Microbot Medical (MBOT) Set to Announce Earnings on Wednesday

Microbot Medical (NASDAQ:MBOT) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Microbot Medical to post earnings of ($0.08) per share and revenue of $0.01 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Microbot Medical (NASDAQ:MBOT) last announced its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. On average, analysts expect Microbot Medical to post ($0.30) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.

Microbot Medical Price Performance

MBOT stock opened at $1.09 on Wednesday. The firm has a 50-day simple moving average of $1.23 and a two-hundred day simple moving average of $1.84. Microbot Medical has a one year low of $0.93 and a one year high of $2.85.

Analysts Set New Price Targets

MBOT has been the topic of several analyst reports. Citizens Jmp started coverage on shares of Microbot Medical in a report on Friday, October 23rd. They issued a “market outperform” rating and a $2.50 price target on the stock. Zacks Research cut Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. B. Riley Financial assumed coverage on Microbot Medical in a research note on Friday, September 11th. They set a “buy” rating and a $4.00 target price on the stock. Wall Street Zen downgraded Microbot Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 24th. Finally, UBS Group set a $2.50 target price on Microbot Medical in a research report on Friday, October 23rd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Microbot Medical has a consensus rating of “Moderate Buy” and a consensus target price of $5.08.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical-device company developing robotic technologies for minimally invasive vascular procedures. Its systems are designed to help physicians remotely control guidewires and catheters during endovascular interventions, with the potential to improve procedural control and reduce clinicians’ exposure to radiation.

The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use robotic platform intended to support peripheral and neurovascular procedures.